Study shows suPAR causes cardiovascular disease

2023-01-26T13:17:39+00:00October 12th, 2022|

STUDY Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis People with kidney disease are disproportionately affected by atherosclerosis for unclear reasons. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived [...]

suPAR levels correlate with disease severity and survival rate of COVID-19 patients, representing a promising prognostic biomarker for the risk assessment of the disease.

2023-01-13T12:52:39+00:00September 5th, 2022|

NEW STUDY Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience Conclusion suPAR levels correlate with disease severity and survival rate of COVID-19 patients, representing a promising prognostic [...]

+800

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 38 hospitals

38 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling. This period covers October 1, 2021, until September 30, 2022.
Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates